Literature DB >> 18565796

Expression profiles and function of Toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients.

Zhiao Chen1, Yuming Cheng, Yongfen Xu, Jing Liao, Xiaonan Zhang, Yunwen Hu, Qin Zhang, Jiefei Wang, Zhanqing Zhang, Fang Shen, Zhenghong Yuan.   

Abstract

Toll-like receptors (TLRs) play a central role in sensing and initiating innate antiviral response. In this study, we first investigated the expression of TLR1-10 mRNA transcripts in peripheral blood mononuclear cells (PBMCs) from chronic HBV-infected (CHB) patients and healthy donors by quantitative real-time PCR. The expression of TLR1, TLR2, TLR4 and TLR6 transcripts was significantly lower in PBMCs from CHB patients, and the down-regulation of TLR2 was related to HBV genotype C. Flow cytometric analysis showed that the expression of TLR2 on PBMCs was significantly decreased in CHB patients. Furthermore, impaired cytokine production was observed in PBMCs from CHB patients after challenged with TLR2 and TLR4 ligands and was correlated with the levels of plasma hepatitis B virus surface antigen (HBsAg). In conclusion, our study reveals a possible interaction between HBsAg, TLR signaling and the innate immune response, which may partially explain the mechanism of HBV infection induced immuno-tolerance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18565796     DOI: 10.1016/j.clim.2008.04.006

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  55 in total

1.  The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases.

Authors:  João-Bruno Soares; Pedro Pimentel-Nunes; Roberto Roncon-Albuquerque; Adelino Leite-Moreira
Journal:  Hepatol Int       Date:  2010-10-21       Impact factor: 6.047

2.  Toll-like receptor and innate cytokine responses induced by lactobacilli colonization and human rotavirus infection in gnotobiotic pigs.

Authors:  Ke Wen; Marli S P Azevedo; Ana Gonzalez; Wei Zhang; Linda J Saif; Guohua Li; Ahmed Yousef; Lijuan Yuan
Journal:  Vet Immunol Immunopathol       Date:  2008-10-31       Impact factor: 2.046

Review 3.  Interplay between hepatitis B virus and the innate immune responses: implications for new therapeutic strategies.

Authors:  Jieliang Chen; Zhenghong Yuan
Journal:  Virol Sin       Date:  2014-01-20       Impact factor: 4.327

4.  Activation of the TLR signaling pathway in CD8+ T cells counteracts liver endothelial cell-induced T cell tolerance.

Authors:  Ejuan Zhang; Hu Yan; Qian Li; Ulf Dittmer; Huimin Yan; Mengji Lu
Journal:  Cell Mol Immunol       Date:  2019-06-26       Impact factor: 11.530

Review 5.  Treatment of hepatitis B virus: an update.

Authors:  Haley Ward; Lydia Tang; Bhawna Poonia; Shyam Kottilil
Journal:  Future Microbiol       Date:  2016-11-18       Impact factor: 3.165

6.  Proteomic analysis of PBMCs: characterization of potential HIV-associated proteins.

Authors:  Lijun Zhang; Xiaofang Jia; Xiaojun Zhang; Jianjun Sun; Xia Peng; Tangkai Qi; Fang Ma; Lin Yin; Yamin Yao; Chao Qiu; Hongzhou Lu
Journal:  Proteome Sci       Date:  2010-03-12       Impact factor: 2.480

Review 7.  Regulation of microRNA by hepatitis B virus infection and their possible association with control of innate immunity.

Authors:  Xia Jiang; Tatsuo Kanda; Shuang Wu; Masato Nakamura; Tatsuo Miyamura; Shingo Nakamoto; Arup Banerjee; Osamu Yokosuka
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

8.  Toll-like receptors as targets in chronic liver diseases.

Authors:  A Mencin; J Kluwe; R F Schwabe
Journal:  Gut       Date:  2009-05       Impact factor: 23.059

Review 9.  Crosstalk between innate and adaptive immunity in hepatitis B virus infection.

Authors:  Li Wang; Kai Wang; Zhi-Qiang Zou
Journal:  World J Hepatol       Date:  2015-12-28

10.  Hepatitis B virus induces expression of cholesterol metabolism-related genes via TLR2 in HepG2 cells.

Authors:  Ying-Ju Li; Ping Zhu; Yu Liang; Wei-Guo Yin; Jian-Hua Xiao
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.